60 results about "Efferent" patented technology

Method and system to provide therapy for obesity and gastrointestinal disorders such as FGIDs, gastroparesis, gastro-esophageal reflex disease (GERD), pancreatitis and ileus comprises vagal blocking and/or vagal stimulation. Vagal blocking may be in the afferent or efferent direction, and may be with or without stimulation pulses. Blocking may be provided by one of a number of different electrical blocking techniques. Electrical signals may be provided with an external stimulator in conjunction with an implanted stimulus-receiver, or an implanted stimulus-receiver comprising a high value capacitor for temporary power source. In one embodiment, the external stimulator may comprise an optional telemetry unit. The addition of the telemetry unit to the external stimulator provides the ability to remotely interrogate and change stimulation programs over a wide area network, as well as other networking capabilities,

A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

Methods and devices for selectively removing an agent from a physiological efferent fluid collection site are provided. A feature of the invention is that a non-occlusive aspiration device is employed to selectively remove the target agent from the site only when the target agent is present in the site. Also provided are systems and kits for performing the subject methods. The subject invention finds use in a variety of different applications, including the selective removal of both therapeutic and diagnostic agents from a variety of different physiological sites.

A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

An intraluminal apparatus including a catheter and device is positionable at a junction of afferent and efferent vessels of a bifurcation having an aneurysm. After positioning the device to substantially conform the device to the shape of the junction, the device acts as a scaffolding to inhibit herniation of objects out of the aneurysm and the device permits perfusion to the efferent vessels. Positioning the device may include deployment and optional release from a catheter. Embolic material may be inserted in the aneurysm before or after positioning the device. The device may have a proximal end, a distal end, and a plurality of filaments extending between and coupled at the proximal end and the distal end. The device may include a central filament configured to reshape the device. The distal end of the device may include a covering. The device may be football shaped, pumpkin shaped, or acorn shaped.

Methods and systems for monitoring, preventing and/or treating upper airway disorders such as apnea, dysphagia, reflux and/or snoring are described. The methods and systems monitor the upper airway disorders by processing one or more neural signals obtained from one or more upper airway afferents. Upper airway disorders are prevented and/or treated by delivering one or more stimulations to one or more reflex-related afferents, efferents, muscles, and sensory receptors to manipulate the threshold and/or trigger an upper airway reflex including, but not limited to a swallow reflex and/or a negative-pressure reflex.

A system for regulating blood pressure by stimulating an afferent pathway to the brain which produces an efferent output in kidneys includes a electrode device adapted for implantation in the cervical region, a stimulator generator, a cable connecting the electrode device and the stimulator generator, wherein the cervical region is generally located between a pair of common carotid arteries, above an aortic arch and in front of cervical vertebrae C2 and C3. A method of implantation includes placing the electrode device in the cervical region, selectively energizing the device in accordance with a stimulation scheme, assessing any changes in the patient's blood pressure, selectively energizing the device in accordance with another stimulation scheme, and assessing any changes in the patient's blood, for determining an optical stimulation scheme, wherein stimulation scheme involves parameters including, for example, position, placement and configuration of the electrode device in relation to surrounding tissue and/or organs, selection of electrodes energized, width, frequency and amplitude of stimulation current.

A vascular remodeling device and methods for its use are provided. The device can be positionable at a junction of a bifurcation having an aneurysm and that defines afferent and efferent vessels. Ends of the device can be at least partially inserted into the aneurysm or can anchor the device by being at least partially inserted into efferent vessels. The device can act as a scaffolding to inhibit dislodging of objects out of the aneurysm. The device can permit perfusion to the efferent vessels. Embolic material can be inserted in the aneurysm before, during, and/or after positioning the device.

A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3.

A system for controlling and modulating a mammalian's body temperature and thermoregulation system includes: a. a display monitor; b. a pulse generator; c. at least one channel of electrical or electromagnetic stimuli connected to the pulse generator, and adapted for cutaneous application on the body's spinal cord; d. a control panel, and e. at least one Measurement Analysis and Command (MAC) unit. The control panel and the MAC units are adapted to implement the optimal stimulating procedure for blocking the afferent neural pathways, evoking the afferent neural pathways, attenuating the afferent neural pathways, blocking and evoking the efferent neural pathways, blocking and attenuating the efferent neural pathways, attenuating and evoking, or blocking, attenuating, and evoking the efferent neural pathways, involved in the thermoregulation system, thereby controlling and modulating the body's temperature and thermoregulation system.